Will nintedanib be included in medical insurance in 2024?

Nintedanib (Nintedanib), as an important therapeutic drug, is increasingly used in the medical field. First, nintedanib is a small molecule tyrosine kinase inhibitor (TKI) that effectively prevents the abnormal proliferation of fibroblasts by binding to the growth factor receptor family. This mechanism has a significant effect in reducing the ongoing fibrotic process and slowing the progression to permanent damage.

Nintedanib is primarily indicated for the treatment and management of a range of fibrosis-related diseases, particularly idiopathic pulmonary fibrosis (IPF), systemic sclerosis-associated interstitial lung disease (SSc-ILD), and interstitial lung diseases (ILD) with progressive phenotypes. These diseases often cause patients' lung function to gradually decline, seriously affecting their quality of life. The emergence of nintedanib has brought new treatment hope to these patients.

As of May 2024, the original drug of nintedanib has been successfully launched in China, and has been strictly reviewed by the National Medical Insurance Bureau and has been included in the reimbursement scope of Class B medical insurance. This means that for patients who meet the indications for nintedanib, they can use national medical insurance to reimburse part of the cost, thereby reducing the financial burden. However, for ineligible patients, if treatment with nintedanib is required, they may be required to pay for the drug out of pocket.

It is worth noting that due to differences in medical insurance policies in various regions, the reimbursement ratio of nintedanib will also vary in various regions. This may result in certain differences in prices after reimbursement. In order to obtain more accurate information, it is recommended that patients or family members consult relevant departments such as local hospitals or medical insurance bureaus to understand specific reimbursement policies and procedures.